The study concluded that THCA-A binds effectively to both cannabinoid receptors, showing a greater affinity for CB1, with Ki values of 23.51 ± 3.5 nM and 56.13 ± 8 and 2 nM, respectively. There is growing interest in the therapeutic use of THCA-A, but its clinical application may be hampered by instability. Therefore, it is possible that the in vivo antinociceptive and anxiolytic effects observed in our study have occurred through these mechanisms, independent of the cannabinoid receptors. Procedure for the rapid isolation of 9-tetrahydrocannabinolic acid A (THCA) from cannabis sativo using two ultra-fast chromatography systems.
DNA methods made it possible to detect THC, cannabinol and tetrahydrocannabinolic acid synthase (THCA) genes in leaf samples as a molecular biology method for identifying extraordinarily well-preserved materials such as the pharmacological form of marijuana. THCA-A affinity studies on CB1 show disparate results equal to THC23 or 25 times weaker than THC24 or lack affinity. HCB1, subtype one of the human cannabinoid receptor; HEK, human embryonic kidney; RCB1, subtype one of the rat cannabinoid receptor; Sf9, clonal isolate 9 from Spodoptera frugiperda; THC, Δ9-tetrahydrocannabinol; THCA-A, Δ9-tetrahydrocannabinolic A. In addition to CP55.940, Â9-THC, Â9-THCA and THCV produced increased antinociceptive effects in mice (Fig.
While there is growing interest in THCA-A among physicians, 3,4 decarboxylation studies suggest that THC contamination is almost inevitable. Specifically, â9-THC, 9-tetrahydrocannabinolic acid (Â9-THCA), â9-tetrahydrocannabivarin (THCV), CBD, cannabidiolic acid (CBDa), cannabidivarin (CBDV), cannabigerol (CBG) and cannabichromene (CBC) were evaluated. However, the loss of THCA-A was substantial in cannabis tea stored at 4°C and decreased to 71% of initial levels after 1 day.
